Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 9/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 9/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345303 | 0.89 | NPC1 (0.39) | AOC3BDKRB1TP53GAA | |
| SCHEMBL4345307 | 0.81 | BDKRB1 (0.38) | AOC3BDKRB1TP53 | |
| SCHEMBL4353756 | 0.80 | AOC3 (0.38) | AOC3BDKRB1TP53 | |
| SCHEMBL3441682 | 0.80 | PSEN1 (0.42) | AVPR1AAVPR1BPSEN1PSEN2APH1B | |
| SCHEMBL700119 | 0.80 | PSEN1 (0.42) | AVPR1AAVPR1BPSEN1PSEN2APH1B | |
| SCHEMBL4348181 | 0.80 | BDKRB1 (0.52) | BDKRB1 | |
| SCHEMBL4348168 | 0.78 | BDKRB1 (0.43) | AOC3BDKRB1 | |
| SCHEMBL4353803 | 0.77 | RAB9A (0.38) | AOC3TP53 | |
| SCHEMBL4345057 | 0.77 | BDKRB1 (0.44) | AOC3BDKRB1 | |
| SCHEMBL2564813 | 0.75 | BDKRB1 (0.59) | BDKRB1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | claimed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | BDKRB2, BDKRB1, TRPV1 | AVPR1A 72/4885AVPR1B 64/4885AOC3 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.